Allied Market Research

2024

Wet Age-related Macular Degeneration (amd) Drugs Market

Wet Age-Related Macular Degeneration (AMD) Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by Type and by END USER : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

  • Jun 2024

  • Pages: NA

  • Tables: NA

  • Charts: NA

Select an option
Online Only (10% Off) $3,690 $3,321
Data Pack/Excel (10% Off) $3,840 $3,456
Single User License (10% Off) $5,820 $5,238
Five User License (10% Off) $6,540 $5,886
Enterprise User License (10% Off) $9,870 $8,883
Library Membership (15% Off) $1,175 $999
Enquiry Now
Author's: | Roshan Deshmukh
Publish Date:
Enquire Before Buying Customization Request Speak with Analyst

Get Sample to Email

  Wet Age-Related Macular Degeneration (AMD) Drugs Market Report Highlights

Aspects Details
icon_5
By Type
  • LUCENTIS
  • AVASTIN
  • EYLEA
  • OTHER DRUGS
icon_6
By END USER
  • HOSPITALS
  • OPHTHALMIC CLINICS
  • RESEARCH INSTITUTES
  • CONTRACT RESEARCH ORGANIZATIONS
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

Novartis AG, Bayer AG, Ophthotech Corporation, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sanofi, Roche Holding AG, Allergan plc, Pfizer Inc., Genentech Inc.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Wet Age-Related Macular Degeneration (AMD) Drugs Market

Global Opportunity Analysis and Industry Forecast, 2023-2032

help@alliedmarketresearch.com